Phase III study in allergic rhinitis awarded

We are proud that Metronomia was awarded a large, multinational phase III study with specific immunotherapy (SIT) in seasonal allergic rhinitis by one of our international clients. Services include providing and supporting of a clincase eCRF, clinical data management, statistical services as well as medical writing.

This repeat business is a further acknowledgement and proof of Metronomia's focus on excellent customer orientation and quality of services.